当身体不适走进一家诊所，没有排队挂号的焦虑，也没有等待医生接诊的漫长，一位"数字医生"在屏幕 后即刻开始问诊是怎样的场景？这并非遥远的科幻设想，而是正在发生的医疗革新。 日前，南都湾财社记者获悉，全球首个真正意义上由AI主导诊疗流程的"AI诊所"，已在沙特阿拉伯落 地，其背后是来自中国的"AI医生"，核心技术来源于中国AI医疗企业森亿智能。 随着大模型技术的飞速发展，"AI+医疗"赛道正迎来新一轮爆发期。据公开数据显示，仅2025年第一季 度，国内医疗器械领域的融资总额已突破80亿元人民币，同比增长显著。 在资本与技术的双重驱动下，AI从辅助走向前台，尝试独立"看诊"，其每一步进展都牵动着行业的神 经，也引发了关于未来医疗模式的广泛讨论。 AI"独立门诊"初体验："无人诊所"如何看病问诊？ 在森亿智能的AI诊所模拟体验区，记者得以一窥这种新型"无人诊所"的运作模式。其核心流程与当前国 内医院普遍应用的AI系统有着本质区别——AI不是只起到辅助作用，而是从幕后走向台前，直接承担 了以往主要由人类医生完成的问诊工作。 患者进入模拟诊室后，首先在一块交互式PAD上通过输入手机号码等方式完成身份信息的初步确认。随 即 ...

据了解，四维医学成立于2008年，前身为上海交通大学医学院医学信息远程监测研发中心，是一家高科 技企业，目前上海交通大学仍拥有其10%股权。作为国内最大规模的远程心电图（ECG）诊断服务解决 方案企业，四维医学主要从事心电图、远程超声影像诊断、人工智能远程诊断创新业务等。 公开资料显示，晶泰控股自2015年由三位麻省理工学院的物理学家创立后，在AI制药领域不断深耕。 2024年6月公司在港交所上市，构建了基于量子物理、以人工智能赋能和机器人驱动的创新型研发平 台。 根据公告，此次收购的对价将以现金方式悉数结清。以四维医学截至2024年12月31日未经审计财务报表 数据来看，2024年公司收入为3961万元，净利润为525万元 。据此计算，此次收购使四维医学全部股权 的市销率为7.0倍，市盈率高达52.9倍。 不过，晶泰控股董事会认为，该交易对价符合与其业务性质相似的五家上市公司的比较数据，公平合 理，符合公司及股东的整体利益。 在业绩承诺方面，长江商报奔腾新闻记者注意到，卖方及担保人向买方承诺，四维医学在截至2025年12 月31日止财政年度来自上海地区项目的主营业务收入不得少于2700万元。尽管这一收入保证 ...

5月8日，湾区未来科技园开园，首批高品质产业空间将投入使用。这个位于深圳市龙岗区宝龙街道的产 业园区，规划用地面积约19万平方米，建筑面积约101万平方米，预计将于2026年全部建成。园区重点 引进生物医药、高端医疗器械、光载信息、人工智能与机器人、新一代电子信息技术等高新技术产业。 同日，位于湾区未来科技园内的AI+生命健康产业园正式揭牌，并吸引亚加达、医友天下等36家AI医疗 行业领军企业意向入驻。AI+生命健康产业园的正式揭牌，对深圳市及龙岗区AI产业，尤其是AI+生命 健康产业意义重大。这意味着龙岗区已经全面开启AI在生物医药领域的深度探索。 龙岗区AI+生命健康产业园是深圳首个AI+健康的产业园区，由龙岗区卫生健康局、龙岗区科技创新局 联合打造，未来将打造成为集"生物医药研发、大健康产品嫁接、医疗器械制造"一体化全方位服务的医 疗健康产业园区及粤港澳大湾区AI+生命健康产业创新高地。 湾区未来科技园效果图。 活动现场举行了入驻企业签约仪式。记者了解到，首批36家意向企业中，已有13家确定入驻AI+生命健 康产业园。众多优质企业汇聚，将形成强大的产业集聚效应，促进资源高效共享与技术的深度交流，为 生命 ...

Core Insights - The article highlights the continuous progress and strategic partnerships of Yidu Technology in the AI healthcare sector, including collaborations with major hospitals and participation in industry conferences [1][3][5] Group 1: Strategic Partnerships and Collaborations - Yidu Technology has established a comprehensive strategic partnership with Beijing Friendship Hospital to co-build a clinical research smart laboratory, focusing on the application of large model technology in medical research [1] - The company collaborated with Peking University Cancer Hospital to develop the "CACA Guideline Assistant," an AI tool that integrates authoritative treatment guidelines with hospital systems to enhance clinical decision-making [17] - Yidu Technology has been the main operator of the "Shenzhen Huiminbao" insurance program for three consecutive years, serving over 34 million insured users across multiple provinces [17] Group 2: Industry Engagement and Recognition - Yidu Technology was recognized as the only AI healthcare company in the "Best IR Hong Kong Company" category at the 8th New Fortune Best IR Awards, reflecting its strong governance and investor relations [19] - The company actively participated in various high-profile industry conferences, sharing insights on how AI can empower public health and improve clinical trial processes [3][5][9] Group 3: Technological Innovations - Yidu Technology showcased its AI-driven solutions for clinical trials at the Future XDC New Drug Conference, emphasizing its end-to-end intelligent research ecosystem [5] - The company reported a significant increase in patient recruitment accuracy for clinical trials, achieving over three times improvement through its self-developed medical large model [13] - The establishment of the "AI Middle Platform" aims to address challenges in hospital smart applications, facilitating a comprehensive digital transformation in healthcare [15] Group 4: Market Position and Future Outlook - Yidu Technology's core advantages in AI healthcare have been recognized by multiple securities firms, with ratings ranging from "Buy" to "Outperform the Market," indicating strong growth potential [22] - The company is positioned to benefit from the increasing adoption of AI technologies in Chinese hospitals, supported by government initiatives [22]

Group 1 - The core viewpoint of the report is that Yidu Technology (医渡科技) is a leading player in the AI healthcare sector in China, receiving an "outperform" rating with a target price of HKD 6.75 [1] - Yidu Technology has developed a robust algorithm engine, YiduCore, which has processed over 5.5 billion medical records, significantly surpassing its competitors [2] - The company's AI-driven solutions have been validated through various assessments, ranking first in multiple standardized evaluations, indicating its technological and medical knowledge advantages [2] Group 2 - The Chinese government's increasing support for AI in healthcare is expected to accelerate industry growth, with new guidelines encouraging the use of AI in medical practices [3] - Yidu Technology is positioned to benefit directly from the trend of hospitals adopting AI technologies, having developed its own core hospital management system [3] - The company has successfully implemented its AI solutions in nearly 30 top medical institutions across China, showcasing its capability to drive deep applications in the healthcare sector [3]

Core Insights - Yidu Technology (2158.HK) has been recognized as one of the "Best IR Hong Kong Companies" by New Fortune, marking the second time the company has received this award and highlighting its governance, investor relations management, and long-term value [2][4] Group 1: Award Recognition - The award reflects the deep recognition from the capital market and investment community regarding the company's governance capabilities and investor relations management [2][4] - Yidu Technology is the only company in the AI medical sector to be included in this prestigious list [2] Group 2: Evaluation Process - The selection process involved an objective quantitative assessment, narrowing down from 326 candidates to the top 60% for final evaluation [4] - A diverse jury composed of regulatory representatives, professional analysts, institutional investors, financial media, and experts conducted the final voting [4] Group 3: Investor Relations Management - Since its listing in Hong Kong in 2021, Yidu Technology has prioritized investor relations through various activities such as performance briefings, technology open days, and investor days [5] - The company has maintained strong communication channels, including investor hotlines and emails, to provide timely updates on business progress [5] Group 4: Technological Innovation - Yidu Technology is a leading player in China's AI medical field, driven by its core algorithm engine, "YiduCore," which has processed over 5.5 billion medical records [5][6] - The company has established an ecosystem covering 2,800 hospitals, leading the market in research business share and real-world research [5] Group 5: Future Outlook - The recent award underscores the strategic foresight of Yidu Technology's dual-driven approach of technological and capital value [6] - As AI medical technology transitions from validation to large-scale commercialization, the company aims to continue driving intelligent upgrades in the medical field, creating long-term value for shareholders and society [6]

来源：环球网 2025年4月24日，中国科大校友企业心之声联合北京大学健康医疗大数据国家研究院正式发布全球首个 生命体征大模型——DeepLife，突破性地实现了对家用医疗器械、可穿戴设备全场景生命体征数据的直 接解析，为用户提供呼吸、循环、神经、消化、泌尿、内分泌、生殖、运动、免疫等9大系统的实时风 险评估与个性化健康管理服务，标志着AI医疗从辅助诊疗迈向主动健康守护的新时代，真正实现"24小 时在线的AI家庭医生" 。 突破性技术：能直接"理解"生命体征数据的大模型 DeepLife的核心优势在于其对生命体征数据的直接理解和分析能力。通过与多种家用医疗器械和可穿戴 设备的无缝对接，DeepLife能够"理解"包括心电、脑电、PPG、呼吸、血氧、血压、血糖等在内的多种 健康数据，并基于个性化数据进行健康状态分析和趋势预测。 并且，DeepLife突破了传统医疗体系的局限，不仅能够对单一健康指标进行解析，还能对人体"九大系 统"进行整体健康风险分析。目前，DeepLife已覆盖ICD-10国际疾病分类中的1859种疾病风险预测，后 续版本将逐步扩展至更多疾病种类。通过"AUROC受试者工作特征曲线下面积"评测 ...

智通财经APP获悉，港股恒生指数涨1.36%，涨297点，报22206点；恒生科技指数涨1.87%。港股早盘成 交1164亿港元。 内房股强势上攻，外资机构看好房地产复苏。花旗集团策略师呼吁投资者增持中国房地产股，因为政策 支持和更好的管理实践预计将提高该行业的盈利能力。金辉控股(09993)飙升逾43%；融信中国(03301) 涨17%；绿城中国（03900）涨5%；旭辉控股(00884)涨7.88%；融创中国（01918）涨4.22%；龙湖集团 （00960）涨6.74%。 AI医疗概念股走高，七部门联合推动AI赋能医药全产业链，机构看好AI医疗产业趋势加速。讯飞医疗 科技(02506)涨7.2%；医渡科技(02158)涨5.35%；晶泰控股(02228)涨4.69%；微创机器人-B(02252)涨 4.07%。 地平线机器人-W(09660)涨超7%，公司与博世达成战略合作 打造博世纵横辅助驾驶升级版。 堃博医疗-B(02216)再涨超14%，本周累计涨幅超95%，核心产品智衡在中国获批上市。 心泰医疗(02291)涨3.88%，公司称控股股东预计销售增长目标存不确定性。 五矿资源(01208)涨逾5% ...

Group 1 - The core viewpoint of the article highlights the positive market response to the announcement of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by the Ministry of Industry and Information Technology and six other departments, which emphasizes the integration of artificial intelligence in the pharmaceutical sector [1] - Companies such as Yidu Tech (02158.HK), Jingtai Holdings (02228.HK), Yimai Tong (02192.HK), and MicroPort Scientific Corporation-B (02252.HK) experienced significant stock price increases, with Yidu Tech rising by 6.27%, Jingtai Holdings by 4.08%, Yimai Tong by 2.13%, and MicroPort by 1.86% following the news [1] - The plan encourages the establishment of innovative platforms for pharmaceutical large models, promoting collaborative research and development of technology products and regulatory science within the industry [1] Group 2 - The initiative aims to strengthen the construction of standards, norms, technological ethics, application safety, and risk management in the pharmaceutical industry [1] - The focus on artificial intelligence applications is expected to enhance the overall efficiency and innovation capacity of the pharmaceutical sector [1]

以下文章来源于乌鸦智能说 ，作者智能乌鸦 乌鸦智能说 . 人人都能读懂的AI商业 今年 2 月，硅谷 AI 营养平台 Fay 完成了由高盛领投的 5000 万美元融资，公司估值冲到 5 亿美元。 据悉，Fay 已经累计融到了 7500 万美元的投资。作为一个连接营养师和患者的在线平台， Fay 凭借仅有不到 3000 个的营养师，实现了 5000 万美金 的年收入。 Fay 极其突出的商业化表现引发了外界对于「AI+医疗」领域的商业化模式思考。 总结来看，Fay 成为 AI 医疗领域「范本」的主要核心优势在于： 通过与保险公司深度绑定，将自身平台嵌入健康保险系统中，Fay 建立了牢固的护城河。 Founder Park 正在搭建开发者社群，邀请积极尝试、测试新模型、新技术的开发者、创业者们加入，请扫码详细填写你的产品/项目信息，通过审核 后工作人员会拉你入群～ 进群之后，你有机会得到： Sammy Faycurry（⾸席执⾏官）和 Mark Stefanski（⾸席技术官） 找准时机，踩中风口： 2022 年以来，美国「减肥潮」兴起，市场对专业营养服务的需求暴增，但营养师的供给严重不足。Fay 基于 AI 技 ...